Veracyte Inc. (VCYT) 5.27 $VCYT
Veracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier
PR Newswire - Fri Jun 10, 8:45PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) preliminary "gapfill" Medicare reimbursement rate for Veracyte's Afirma Gene Expression Classifier (GEC), which the agency released this afternoon.
VCYT: 5.27 (-0.10)
Veracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36th Annual Growth Stock Conference on Wednesday, June 15th, 2016 at 2:40 p.m. CT in Chicago, IL.
VCYT: 5.27 (-0.10)
Veracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis
PR Newswire - Fri May 27, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following routine cytopathology evaluation. Company researchers also unveiled a new study designed to identify RNA-based gene alteration and other data that may be useful in guiding physician decision-making for thyroid nodule patients. The studies are being presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress, taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 5.27 (-0.10)
Veracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress
PR Newswire - Mon May 23, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that company scientists and external researchers will present new data advancing the science around the role of gene alterations and transcriptions in thyroid cancer diagnosis at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 5.27 (-0.10)
New Data Demonstrating Ability of Veracyte's Genomic Test to Improve Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2016
PR Newswire - Tue May 17, 4:30PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company's in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without the need for invasive and potentially risky surgery. Additional data from three other studies suggest the potential for the test to address several challenges that currently hinder accurate and timely diagnosis of the disease. The findings were presented at the American Thoracic Society (ATS) 2016 International Conference taking place May 13-18 in San Francisco.
VCYT: 5.27 (-0.10)
Veracyte reports 1Q loss
Automated Insights - Thu May 05, 4:15PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $10.1 million in its first quarter.
VCYT: 5.27 (-0.10)
Veracyte Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. For the first quarter of 2016, revenue was $13.6 million, an increase of 21%, compared to $11.2 million for the first quarter of 2015. Afirma Gene Expression Classifier (GEC) test volume grew to 5,352 tests, an increase of 33%, compared to the same period in 2015.
VCYT: 5.27 (-0.10)
/C O R R E C T I O N -- Veracyte/
PR Newswire - Tue Apr 19, 11:01AM CDT
In the news release, Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016, issued 19-Apr-2016 by Veracyte over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016" rather than "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, May 5, 2016" as originally issued inadvertently. The complete, corrected release follows:
VCYT: 5.27 (-0.10)
Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016
PR Newswire - Sat Apr 02, 12:15PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from two new studies demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC). The genomic test is used to rule out cancer in thyroid nodules deemed indeterminate (not clearly benign or malignant) following traditional cytopathology evaluation so that these patients can potentially avoid an unnecessary surgery. The findings were presented today at ENDO 2016, the annual meeting of the Endocrine Society, being held April 1-4 in Boston.
VCYT: 5.27 (-0.10)
Multiple Studies Showcasing Clinical Utility of Veracyte's Afirma® Gene Expression Classifier to Be Presented at ENDO 2016
PR Newswire - Tue Mar 29, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that company and external researchers will deliver poster presentations demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC) in thyroid cancer diagnosis, as well as advancing the genomic science around thyroid malignancy, at ENDO 2016, the annual conference of The Endocrine Society, being held April 1-4 in Boston.
VCYT: 5.27 (-0.10)
Veracyte Secures Up to $45 Million in Financing from Visium Healthcare Partners
PR Newswire - Mon Mar 28, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, and Visium Healthcare Partners, LP, a healthcare investment firm, today announced that they have entered into an agreement that provides up to $45 million of financing, comprising a term loan agreement and securities purchase option. On a pro forma basis, net proceeds from the new loan facility and the cash and cash equivalents as of December 31, 2015 provide Veracyte with approximately $73 million to fund the continued growth of the company's core business.
VCYT: 5.27 (-0.10)
New Study Supports Use of Veracyte's Medullary Thyroid Cancer Classifier as Part of Its Comprehensive Afirma Solution
PR Newswire - Tue Mar 22, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data from a large, prospective clinical study demonstrate the accuracy of the company's medullary thyroid cancer (MTC) classifier and its potential - when used with the Afirma® Gene Expression Classifier (GEC) - to provide a more clinically useful way to diagnose this aggressive cancer preoperatively, compared to traditional methods. The findings are published online in the journal Thyroid.
VCYT: 5.27 (-0.10)
New Data Show That Veracyte's Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
PR Newswire - Wed Mar 16, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced publication of data demonstrating that the Afirma Gene Expression Classifier (GEC) reduces unnecessary surgeries in thyroid cancer diagnosis during long-term clinical follow-up. The study is the first to use a national healthcare claims database to determine the real-world impact of the genomic test on patient care and to quantify the costs associated with thyroid surgery. The findings appear online in the journal Current Medical Research & Opinion.
VCYT: 5.27 (-0.10)
Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook
PR Newswire - Thu Mar 10, 3:05PM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2015, and provided financial guidance for 2016.
VCYT: 5.27 (-0.10)
Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
PR Newswire - Fri Feb 19, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that an independent clinical utility study reinforcing the ability of the Afirma Gene Expression Classifier (GEC) to significantly reduce unnecessary surgeries in thyroid cancer diagnosis was published in the February issue of Cancer Cytopathology.
VCYT: 5.27 (-0.10)
Veracyte Receives Regulatory Authorization to Offer Percepta(TM) Bronchial Genomic Classifier for Patients in New York State
PR Newswire - Thu Jan 28, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta(TM) Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans.
VCYT: 5.27 (-0.10)
Veracyte to Participate in Two Upcoming Investor Conferences
PR Newswire - Wed Jan 27, 7:00AM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.
VCYT: 5.27 (-0.10)
Air Methods (AIRM) Completes Tri-State Care Flight Buyout
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 12:10PM CST
Air Methods (AIRM) recently completed the previously announced acquisition of Tri-State Care Flight for $22.5 million.
ISRG: 641.59 (-6.61), VCYT: 5.27 (-0.10), AIRM: 36.18 (-0.92), EXAC: 25.42 (+0.12)
Veracyte Announces Expansion to New South San Francisco Facility
PR Newswire - Thu Jan 07, 3:10PM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that the company is relocating to expanded laboratory and corporate space within South San Francisco. The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.
VCYT: 5.27 (-0.10)
Veracyte Statement on CMS's Preliminary Gapfill Rate for the Afirma® Gene Expression Classifier
PR Newswire - Fri Jun 10, 8:45PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) preliminary "gapfill" Medicare reimbursement rate for Veracyte's Afirma Gene Expression Classifier (GEC), which the agency released this afternoon.
VCYT: 5.27 (-0.10)
Veracyte to Present at the William Blair & Company 36th Annual Growth Stock Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that Chris Hall, chief operating officer, will present at the William Blair & Company 36th Annual Growth Stock Conference on Wednesday, June 15th, 2016 at 2:40 p.m. CT in Chicago, IL.
VCYT: 5.27 (-0.10)
Veracyte Announces New Data that Advance Understanding of the Role of Gene Alterations In Thyroid Cancer Diagnosis
PR Newswire - Fri May 27, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from two studies demonstrating the challenge of using large gene-mutation panels to help physicians determine next steps for patients whose thyroid nodules are not clearly benign or malignant following routine cytopathology evaluation. Company researchers also unveiled a new study designed to identify RNA-based gene alteration and other data that may be useful in guiding physician decision-making for thyroid nodule patients. The studies are being presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress, taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 5.27 (-0.10)
Veracyte Announces Data from Multiple Studies Advancing Scientific Understanding of Thyroid Cancer to Be Presented at AACE Congress
PR Newswire - Mon May 23, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that company scientists and external researchers will present new data advancing the science around the role of gene alterations and transcriptions in thyroid cancer diagnosis at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress taking place May 25-29, 2016, in Orlando, Fla.
VCYT: 5.27 (-0.10)
New Data Demonstrating Ability of Veracyte's Genomic Test to Improve Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2016
PR Newswire - Tue May 17, 4:30PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from a new study demonstrating the potential for the company's in-development Envisia classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without the need for invasive and potentially risky surgery. Additional data from three other studies suggest the potential for the test to address several challenges that currently hinder accurate and timely diagnosis of the disease. The findings were presented at the American Thoracic Society (ATS) 2016 International Conference taking place May 13-18 in San Francisco.
VCYT: 5.27 (-0.10)
Veracyte reports 1Q loss
Automated Insights - Thu May 05, 4:15PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a loss of $10.1 million in its first quarter.
VCYT: 5.27 (-0.10)
Veracyte Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. For the first quarter of 2016, revenue was $13.6 million, an increase of 21%, compared to $11.2 million for the first quarter of 2015. Afirma Gene Expression Classifier (GEC) test volume grew to 5,352 tests, an increase of 33%, compared to the same period in 2015.
VCYT: 5.27 (-0.10)
/C O R R E C T I O N -- Veracyte/
PR Newswire - Tue Apr 19, 11:01AM CDT
In the news release, Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on Thursday, May 5, 2016, issued 19-Apr-2016 by Veracyte over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2016 financial results after close of market on Thursday, May 5, 2016" rather than "Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, May 5, 2016" as originally issued inadvertently. The complete, corrected release follows:
VCYT: 5.27 (-0.10)
Clinical Utility of Veracyte's Afirma® Gene Expression Classifier Demonstrated in Multiple Studies Presented at ENDO 2016
PR Newswire - Sat Apr 02, 12:15PM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced findings from two new studies demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC). The genomic test is used to rule out cancer in thyroid nodules deemed indeterminate (not clearly benign or malignant) following traditional cytopathology evaluation so that these patients can potentially avoid an unnecessary surgery. The findings were presented today at ENDO 2016, the annual meeting of the Endocrine Society, being held April 1-4 in Boston.
VCYT: 5.27 (-0.10)
Multiple Studies Showcasing Clinical Utility of Veracyte's Afirma® Gene Expression Classifier to Be Presented at ENDO 2016
PR Newswire - Tue Mar 29, 3:05PM CDT
Veracyte, Inc. (NASDAQ: VCYT) today announced that company and external researchers will deliver poster presentations demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC) in thyroid cancer diagnosis, as well as advancing the genomic science around thyroid malignancy, at ENDO 2016, the annual conference of The Endocrine Society, being held April 1-4 in Boston.
VCYT: 5.27 (-0.10)
Veracyte Secures Up to $45 Million in Financing from Visium Healthcare Partners
PR Newswire - Mon Mar 28, 7:00AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, and Visium Healthcare Partners, LP, a healthcare investment firm, today announced that they have entered into an agreement that provides up to $45 million of financing, comprising a term loan agreement and securities purchase option. On a pro forma basis, net proceeds from the new loan facility and the cash and cash equivalents as of December 31, 2015 provide Veracyte with approximately $73 million to fund the continued growth of the company's core business.
VCYT: 5.27 (-0.10)
New Study Supports Use of Veracyte's Medullary Thyroid Cancer Classifier as Part of Its Comprehensive Afirma Solution
PR Newswire - Tue Mar 22, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that data from a large, prospective clinical study demonstrate the accuracy of the company's medullary thyroid cancer (MTC) classifier and its potential - when used with the Afirma® Gene Expression Classifier (GEC) - to provide a more clinically useful way to diagnose this aggressive cancer preoperatively, compared to traditional methods. The findings are published online in the journal Thyroid.
VCYT: 5.27 (-0.10)
New Data Show That Veracyte's Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
PR Newswire - Wed Mar 16, 6:30AM CDT
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced publication of data demonstrating that the Afirma Gene Expression Classifier (GEC) reduces unnecessary surgeries in thyroid cancer diagnosis during long-term clinical follow-up. The study is the first to use a national healthcare claims database to determine the real-world impact of the genomic test on patient care and to quantify the costs associated with thyroid surgery. The findings appear online in the journal Current Medical Research & Opinion.
VCYT: 5.27 (-0.10)
Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook
PR Newswire - Thu Mar 10, 3:05PM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2015, and provided financial guidance for 2016.
VCYT: 5.27 (-0.10)
Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
PR Newswire - Fri Feb 19, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that an independent clinical utility study reinforcing the ability of the Afirma Gene Expression Classifier (GEC) to significantly reduce unnecessary surgeries in thyroid cancer diagnosis was published in the February issue of Cancer Cytopathology.
VCYT: 5.27 (-0.10)
Veracyte Receives Regulatory Authorization to Offer Percepta(TM) Bronchial Genomic Classifier for Patients in New York State
PR Newswire - Thu Jan 28, 6:30AM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta(TM) Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans.
VCYT: 5.27 (-0.10)
Veracyte to Participate in Two Upcoming Investor Conferences
PR Newswire - Wed Jan 27, 7:00AM CST
Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th 2016 at 11:05 a.m. ET in New York, NY.
VCYT: 5.27 (-0.10)
Air Methods (AIRM) Completes Tri-State Care Flight Buyout
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 12:10PM CST
Air Methods (AIRM) recently completed the previously announced acquisition of Tri-State Care Flight for $22.5 million.
ISRG: 641.59 (-6.61), VCYT: 5.27 (-0.10), AIRM: 36.18 (-0.92), EXAC: 25.42 (+0.12)
Veracyte Announces Expansion to New South San Francisco Facility
PR Newswire - Thu Jan 07, 3:10PM CST
Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that the company is relocating to expanded laboratory and corporate space within South San Francisco. The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.
VCYT: 5.27 (-0.10)
